|
1
|
Liao JK and Laufs U: Pleiotropic effects
of statins. Annu Rev Pharmacol Toxicol. 45:89–118. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Goldstein JL and Brown MS: Regulation of
the mevalonate pathway. Nature. 343:425–430. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ganesh SK, Nass CM and Blumenthal RS:
Anti-atherosclerotic effects of statins: Lessons from prevention
trials. J Cardiovasc Risk. 10:155–159. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
LaRosa JC: Statins and risk of coronary
heart disease. JAMA. 283:2935–2936. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Clemenson ND: Statins and risk of coronary
heart disease. JAMA. 283:29352000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Klag MJ, Ford DE, Mead LA, He J, Whelton
PK, Liang KY and Levine DM: Serum cholesterol in young men and
subsequent cardiovascular disease. N Engl J Med. 328:313–318. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Goldstein JL and Brown MS: A century of
cholesterol and coronaries: From plaques to genes to statins. Cell.
26:161–72. 2015. View Article : Google Scholar
|
|
8
|
Massy ZA, Keane WF and Kasiske BL:
Inhibition of the mevalonate pathway: Benefits beyond cholesterol
reduction? Lancet. 347:102–103. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wierzbicki AS, Poston R and Ferro A: The
lipid and non-lipid effects of statins. Pharmacol Ther. 99:95–112.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Influence of pravastatin and plasma lipids
on clinical events in the West of Scotland Coronary Prevention
Study (WOSCOPS). Circulation. 97:1440–1445. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Laufs U: Beyond lipid-lowering: Effects of
statins on endothelial nitric oxide. Eur J Clin Pharmacol.
58:719–731. 2003.PubMed/NCBI
|
|
12
|
Hilbert T, Poth J, Frede S, Klaschik S,
Hoeft A, Baumgarten G and Knuefermann P: Anti-atherogenic effects
of statins: Impact on angiopoietin-2 release from endothelial
cells. Biochem Pharmacol. 86:1452–1460. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Moncada S, Palmer RM and Higgs EA: Nitric
oxide: Physiology, pathophysiology and pharmacology. Pharmacol Rev.
43:109–142. 1991.PubMed/NCBI
|
|
14
|
Rabelink TJ and Luscher TF: Endothelial
nitric oxide synthase: Host defense enzyme of the endothelium?
Arterioscler Thromb Vasc Biol. 26:267–271. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sukhova GK, Williams JK and Libby P:
Statins reduce inflammation in atheroma of nonhuman primates
independent of effects on serum cholesterol. Arterioscler Thromb
Vasc Biol. 22:1452–1458. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Giroux LM, Davignon J and Naruszewicz M:
Simvastatin inhibits the oxidation of low-density lipoproteins by
activated human monocyte-derived macrophages. Biochim Biophys Acta.
1165:335–338. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Arnaud C, Braunersreuther V and Mach F:
Toward immunomodulatory and anti-inflammatory properties of
statins. Trends Cardiovasc Med. 15:202–206. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kumai T, Matsumoto N, Koitabashi Y, Takeba
Y, Oonuma S, Sekine S, Tadokoro M and Kobayashi S: Pleiotropic
effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase
inhibitors: Candidate mechanisms for anti-lipid deposition in blood
vessels. Curr Med Chem Cardiovasc Hematol Agents. 3:195–201. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rasmussen LM, Hansen PR, Nabipour MT,
Olesen P, Kristiansen MT and Ledet T: Diverse effects of inhibition
of 3-hydroxy-3-methylglutaryl-CoA reductase on the expression of
VCAM-1 and E-selectin in endothelial cells. Biochem J. 360:363–370.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liles WC and Kain KC: Endothelial
activation and dysfunction in the pathogenesis of microvascular
obstruction in severe malaria-a viable target for therapeutic
adjunctive intervention. J Infect Dis. 210:163–164. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Alvarez De Sotomayor M, Herrera MD,
Marhuenda E and Andriantsitohaina R: Characterization of
endothelial factors involved in the vasodilatory effect of
simvastatin in aorta and small mesenteric artery of the rat. Br J
Pharmacol. 131:1179–1187. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bonetti PO, Lerman LO and Lerman A:
Endothelial dysfunction: A marker of atherosclerotic risk.
Arterioscler Thromb Vasc Biol. 23:168–175. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Matthys KE and Bult H: Nitric oxide
function in atherosclerosis. Mediators Inflamm. 6:3–21. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ross R: The pathogenesis of
atherosclerosis: A perspective for the 1990s. Nature. 362:801–809.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Noll G, Tschudi M, Nava E and Lüscher TF:
Endothelium and high blood pressure. Int J Microcirc Clin Exp.
17:273–279. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kita T, Brown MS and Goldstein JL:
Feedback regulation of 3-hydroxy-3-methylglutaryl coenzyme A
reductase in livers of mice treated with mevinolin, a competitive
inhibitor of the reductase. J Clin Invest. 66:1094–1100. 1980.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang TH, Peng G, Li GQ, Yamahara J,
Roufogalis BD and Li Y: Salacia oblonga root improves postprandial
hyperlipidemia and hepatic steatosis in Zucker diabetic fatty rats:
Activation of PPAR-alpha. Toxicol Appl Pharmacol. 210:225–235.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hitosugi T, Kang S, Vander Heiden MG,
Chung TW, Elf S, Lythgoe K, Dong S, Lonial S, Wang X, Chen GZ, et
al: Tyrosine phosphorylation inhibits PKM2 to promote the Warburg
effect and tumor growth. Sci Signal. 2:ra732009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lang F, Henke G, Embark HM, Waldegger S,
Palmada M, Böhmer C and Vallon V: Regulation of channels by the
serum and glucocorticoid-inducible kinase - implications for
transport, excitability and cell proliferation. Cell Physiol
Biochem. 13:41–50. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Husain M, Jiang L, See V, Bein K, Simons
M, Alper SL and Rosenberg RD: Am J Physiol. 272:C1947–C1959.
1997.PubMed/NCBI
|
|
31
|
Gadepalli R, Singh NK, Kundumani-Sridharan
V, Heckle MR and Rao GN: Novel role of proline-rich nonreceptor
tyrosine kinase 2 in vascular wall remodeling after balloon injury.
Arterioscler Thromb Vasc Biol. 32:2652–2661. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Slattery ML, Lundgreen A and Wolff RK: MAP
kinase genes and colon and rectal cancer. Carcinogenesis.
33:2398–2408. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vogler M: Targeting BCL2-proteins for the
treatment of solid tumours. Adv Med. 2014:9436482014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tse KW, Lin KB, Dang-Lawson M,
Guzman-Perez A, Aspnes GE, Buckbinder L and Gold MR: Small molecule
inhibitors of the Pyk2 and FAK kinases modulate
chemoattractant-induced migration, adhesion and Akt activation in
follicular and marginal zone B cells. Cell Immunol. 275:47–54.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Maddika S, Ande SR, Panigrahi S,
Paranjothy T, Weglarczyk K, Zuse A, Eshraghi M, Manda KD, Wiechec E
and Los M: Cell survival, cell death and cell cycle pathways are
interconnected: implications for cancer therapy. Drug Resist Updat.
10:13–29. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nemoto S, Kobayashi T, Taguchi K,
Matsumoto T and Kamata K: Losartan improves aortic
endothelium-dependent relaxation via proline-rich tyrosine kinase
2/Src/Akt pathway in type 2 diabetic Goto-Kakizaki rats. Am J
Physiol Heart Circ Physiol. 301:H2383–H2394. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hilbert T, Poth J, Frede S, Klaschik S,
Hoeft A, Baumgarten G and Knuefermann P: Anti-atherogenic effects
of statins: Impact on angiopoietin-2 release from endothelial
cells. Biochem Pharmacol. 86:1452–1460. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang Y, Zhou D, Phung S, Masri S, Smith D
and Chen S: SGK3 is an estrogen-inducible kinase promoting
estrogen-mediated survival of breast cancer cells. Mol Endocrinol.
25:72–82. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Maier G, Palmada M, Rajamanickam J,
Shumilina E, Böhmer C and Lang F: Upregulation of HERG channels by
the serum and glucocorticoid inducible kinase isoform SGK3. Cell
Physiol Biochem. 18:177–186. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Burdick AD, Ivnitski-Steele ID, Lauer FT
and Burchiel SW: PYK2 mediates anti-apoptotic AKT signaling in
response to benzo[a]pyrene diol epoxide in mammary epithelial
cells. Carcinogenesis. 27:2331–2340. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Cao J, Chen Y, Fu J, Qian YW, Ren YB, Su
B, Luo T, Dai RY, Huang L, Yan JJ, et al: High expression of
proline-rich tyrosine kinase 2 is associated with poor survival of
hepatocellular carcinoma via regulating phosphatidylinositol
3-kinase/AKT pathway. Ann Surg Oncol. 20(Suppl 3): S312–S323. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Daou GB and Srivastava AK: Reactive oxygen
species mediate Endothelin-1-induced activation of ERK1/2, PKB and
Pyk2 signaling, as well as protein synthesis, in vascular smooth
muscle cells. Free Radic Biol Med. 37:208–215. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sun CK, Man K, Ng KT, Ho JW, Lim ZX, Cheng
Q, Lo CM, Poon RT and Fan ST: Proline-rich tyrosine kinase 2 (Pyk2)
promotes proliferation and invasiveness of hepatocellular carcinoma
cells through c-Src/ERK activation. Carcinogenesis. 29:2096–2105.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ross R: Atherosclerosis - an inflammatory
disease. N Engl J Med. 340:115–126. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kugiyama K, Kerns SA, Morrisett JD,
Roberts R and Henry PD: Impairment of endothelium-dependent
arterial relaxation by lysolecithin in modified low-density
lipoproteins. Nature. 344:160–162. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Simon BC, Cunningham LD and Cohen RA:
Oxidized low density lipoproteins cause contraction and inhibit
endothelium-dependent relaxation in the pig coronary artery. J Clin
Invest. 86:75–79. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Dimmeler S, Haendeler J, Galle J and
Zeiher AM: Oxidized low-density lipoprotein induces apoptosis of
human endothelial cells by activation of CPP32-like proteases. A
mechanistic clue to the ‘response to injury’ hypothesis.
Circulation. 95:1760–1763. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Harada-Shiba M, Kinoshita M, Kamido H and
Shimokado K: Oxidized low density lipoprotein induces apoptosis in
cultured human umbilical vein endothelial cells by common and
unique mechanisms. J Biol Chem. 273:9681–9687. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chavakis E, Dernbach E, Hermann C, Mondorf
UF, Zeiher AM and Dimmeler S: Oxidized LDL inhibits vascular
endothelial growth factor-induced endothelial cell migration by an
inhibitory effect on the Akt/endothelial nitric oxide synthase
pathway. Circulation. 103:2102–2107. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Kotamraju S, Hogg N, Joseph J, Keefer LK
and Kalyanaraman B: Inhibition of oxidized low-density
lipoprotein-induced apoptosis in endothelial cells by nitric oxide:
Peroxyl radical scavenging as an antiapoptotic mechanism. J Biol
Chem. 276:17316–17323. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Sun CK, Ng KT, Lim ZX, Cheng Q, Lo CM,
Poon RT, Man K, Wong N and Fan ST: Proline-rich tyrosine kinase 2
(Pyk2) promotes cell motility of hepatocellular carcinoma through
induction of epithelial to mesenchymal transition. PLoS One.
6:e188782011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Lim ST, Miller NL, Nam JO, Chen XL, Lim Y
and Schlaepfer DD: Pyk2 inhibition of p53 as an adaptive and
intrinsic mechanism facilitating cell proliferation and survival. J
Biol Chem. 285:1743–1753. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Yoon H, Choi YL, Song JY, Do I, Kang SY,
Ko YH, Song S and Kim BG: Targeted inhibition of FAK, PYK2 and
BCL-XL synergistically enhances apoptosis in ovarian clear cell
carcinoma cell lines. PLoS One. 9:e885872014. View Article : Google Scholar : PubMed/NCBI
|
